3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
4
Lung Neoplasms
3
Thymoma
2
Mesothelioma, Malignant
2
Esophageal Neoplasms
2
Solid Tumor, Adult
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Mesothelioma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
14
Injections
13
Paclitaxel
10
Nivolumab
10
Docetaxel
9
Cisplatin
9
Capecitabine
9
Bevacizumab
8
toripalimab
7
senaparib
7
Fluorodeoxyglucose F18
7
Cyclophosphamide
7
tislelizumab
6
atezolizumab
6
Irinotecan
6
Fluorouracil
6
Gemcitabine
5
fludarabine
4
apatinib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Carboplatin
4
spartalizumab
3
sintilimab
3
pertuzumab
3
olaparib
3
camrelizumab
3
Rifampin
3
Radiosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solid Tumor
×
Celecoxib
×
Other solid neoplasm
×
Clear all
NCT04469530
2026-02-27
AflacST1903
Emory University
Phase 2
Recruiting
55 enrolled